Retronectin-induced T cell therapy - Takara Bio

Drug Profile

Retronectin-induced T cell therapy - Takara Bio

Alternative Names: Cancer immunity reconstruction therapy; Cell-based cancer immunotherapy

Latest Information Update: 13 May 2014

Price : $50

At a glance

  • Originator Takara Bio
  • Developer Kyoto Prefectural University of Medicine; Takara Bio; Tianjin Medical University Cancer Institute and Hospital
  • Class Antineoplastics; Gene therapies; T lymphocyte cell therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Gastrointestinal cancer; Liver cancer; Lung cancer; Pancreatic cancer
  • No development reported Cancer

Most Recent Events

  • 13 May 2014 Clinical development is ongoing in Japan
  • 13 May 2014 No development reported - Phase-I/II for Cancer in China (Parenteral)
  • 02 May 2008 Phase-I/II clinical trials in Cancer in China (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top